"We're running in the Gold Coast Marathon events 6-7th July 2019 to make a difference by: a) supporting people with ME/CFS, and b) to raise much needed money for Emerge Australia Inc. To support our cause, please help by giving whatever you can using the Give Now button, and sharing our journey with your friends and family. The more people that know about Emerge Australia, the greater their impact. Thank you in advance for your generosity, it means a lot!" – Andrew
"I'm so grateful to my family for their understanding and support of an illness that has taken so much from me, and up to 250,000 other Australians! We hope to raise $2000 for Emerge Australia and we plan to match that number, by donating another $2000 (of our own personal savings) directly to much needed biomedical research happening on the Gold Coast with Griffith University’s National Centre for Neuroimmunology and Emerging Diseases (NCNED) Alison Hunter Memorial Fund (a young Australian who lost her life due to complications of having ME/CFS). Your support is greatly appreciated." – Amanda
Update: 10th April - we smashed our goal of $2000 for Emerge Australia and as promised, we donated $2000 directly to biomedical research happening on the Gold Coast - Griffith University’s National Centre for Neuroimmunology & Emerging Diseases (AHMF donors) - We've received a lovely letter from Griffith University thanking us and even a post on their facebook page. The NCNED are doing a fantastic job... here's their latest publication:
1. Impaired TRPM3 activity for potential biomarker was further validated in NK cells isolated from CFS/ME patients
2. These results for identification of pathology have been confirmed in a new cohort of CFS/ME patients and healthy participants.
3. NCNED Researchers used nifedipine, a known drug used by CFS/ME patients and a reversible TRPM3 agonist to treat NK cells from CFS/ME patients.
4. Nifedipine, confirmed a significant loss of the TRPM3 channel activity in CFS/ME patients and pathology of this family of receptors in this illness.
5. TRPM3 is not only confirmed in the pathology of CFS/ME but now considered as a potential biomarker and targeted for treatment for CFS/ME
6. NCNED is now trialing other drugs to target TRP channels for benefiting CFS/ME patients.
For more info:
Griffith Uni's NCNED -
To read about Emerge Australia Inc please refer to 'read more' under their logo at the right of this page.
Gold Coast Marathon Page - https://goldcoastmarathon.com.au